Circulating progenitor cells in patients with familial hypercholesterolemia
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21601
Abstract: Familial hypercholesterolemia (FH) is a genetic disease with very high levels of circulating low density lipoprotein cholesterol (LDL‐C) levels that leads to accelerated atherosclerosis. Lipoprotein apheresis is an effective treatment option for patients with FH… read more here.
Keywords: progenitor cells; circulating progenitor; apheresis; familial hypercholesterolemia ... See more keywords
Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21839
Abstract: Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid‐lowering therapies. Lipoprotein apheresis (LA) has long been a standard of care for patients with severe… read more here.
Keywords: lipoprotein apheresis; familial hypercholesterolaemia; pcsk9 inhibitors; severe familial ... See more keywords
[Lipoprotein apheresis : State of the art and case report of the longest HELP treatment worldwide].
Sign Up to like & getrecommendations! Published in 2022 at "Herz"
DOI: 10.1007/s00059-022-05115-9
Abstract: Lipoprotein apheresis is an extracorporeal procedure for the treatment of patients with homozygous familial hypercholesterolemia, patients with severe treatment-resistant hypercholesterolemia and patients with lipoprotein(a) hypercholesterolemia, who show progressive atherosclerotic cardiovascular disease despite optimal treatment. This… read more here.
Keywords: apheresis; hypercholesterolemia; treatment; case ... See more keywords
Direct oral anticoagulants in lipoprotein apheresis: handle with care
Sign Up to like & getrecommendations! Published in 2019 at "Internal and Emergency Medicine"
DOI: 10.1007/s11739-019-02118-z
Abstract: Since 2009, direct oral anticoagulants (DOAC) are increasingly being used in clinical practice for stroke prevention in non-valvular atrial fibrillation and in treatment/prevention of thromboembolism. Their correct management is not only a concern for internal… read more here.
Keywords: medicine; oral anticoagulants; direct oral; therapy ... See more keywords
Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
Sign Up to like & getrecommendations! Published in 2018 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2018.08.007
Abstract: BACKGROUND AND AIMS Lipoprotein apheresis (LA) is a complex therapeutic option and poor compliance can adversely affect treatment outcome. The aim of this study was to describe long-term compliance to treatment in patients undergoing regular… read more here.
Keywords: long term; treatment; compliance; familial hypercholesterolemia ... See more keywords
Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2019.09.010
Abstract: BACKGROUND Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with… read more here.
Keywords: reduction; united states; cvd; lipoprotein apheresis ... See more keywords
The German Lipoprotein Apheresis Registry—Summary of the ninth annual report
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13780
Abstract: During 2012–2020, 89 German apheresis centers collected retrospective and prospective observational data of 2028 patients undergoing regular lipoprotein apheresis (LA) for the German Lipoprotein Apheresis Registry (GLAR). More than 47 500 LA sessions are documented in… read more here.
Keywords: registry summary; apheresis; lipoprotein apheresis; german lipoprotein ... See more keywords
Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13856
Abstract: Patients with homozygous familial hypercholesterolemia (FH) have severe hypercholesterolemia from birth and if untreated may experience very early onset of coronary artery disease in childhood or young adulthood with an aggressive course resulting in early… read more here.
Keywords: hypercholesterolemia; homozygous familial; patients homozygous; combination lipoprotein ... See more keywords
Beyond cholesterol—pleiotropic effects of lipoprotein apheresis
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13857
Abstract: Cardiovascular disease is a leading cause of mortality worldwide, which is caused mainly by atherosclerosis, a chronic inflammatory disease of blood vessels. Therefore, atherosclerosis represents a complex disorder, which induces damage or imbalance on different… read more here.
Keywords: beyond cholesterol; apheresis; pleiotropic effects; effects lipoprotein ... See more keywords
Repeated lipoprotein apheresis and immune response: Effects on different immune cell populations
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13886
Abstract: Atherosclerosis is considered a chronic inflammation of arterial vessels with the involvement of several immune cells causing severe cardiovascular diseases. Lipoprotein apheresis (LA) improves cardiovascular conditions of patients with severely disturbed lipid metabolism. In this… read more here.
Keywords: apheresis; immune cell; lipoprotein apheresis; cell populations ... See more keywords